New formulation of Abbott's Lupron Depot receives US FDA approval
This article was originally published in Scrip
Executive Summary
Abbott has received approval from the US FDA for a new six-month formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer?.